We could not find any results for:
Make sure your spelling is correct or try broadening your search.
Register to chat with like-minded investors on our interactive forums.
| Share Name | Share Symbol | Market | Type | Share ISIN | Share Description |
|---|---|---|---|---|---|
| Incanthera plc | AQSE:INC | Aquis Stock Exchange | Ordinary Share | GB00BGL7YW15 |
| Price Change | % Change | Share Price | Bid Price | Offer Price | High Price | Low Price | Open Price | Shares Traded | Last Trade | |
|---|---|---|---|---|---|---|---|---|---|---|
| 0.3499 | 2.59% | 13.8499 | 13.00 | 14.00 | 13.8499 | 13.00 | 13.50 | 20,761 | 13:37:21 |
| Industry Sector | Turnover | Profit | EPS - Basic | PE Ratio | Market Cap |
|---|---|---|---|---|---|
| 0 | 0 | N/A | 0 |
From Apr 2022 to Apr 2024
TIDMINC
RNS Number : 8702A
Incanthera PLC
27 September 2022
27 September 2022
Incanthera plc
("Incanthera" or the "Company")
Result of AGM 2022
Incanthera plc (AQSE: INC), the specialist oncology company focused on innovative technologies in oncology and dermatology, held its AGM earlier today. The Company is pleased to announce that all resolutions were duly passed.
The Company would like to thank all Shareholders who returned their Proxy form and attended in person.
For further enquiries:
Incanthera plc www.incanthera.com Tim McCarthy, Chairman tim.mccarthy@incanthera.com +44 (0) 7831 675747 Simon Ward, Chief Executive Officer simon.ward@incanthera.com +44 (0) 7747 625506 Suzanne Brocks, Head of Communications suzanne.brocks@incanthera.com +44 (0) 7776 234600 Aquis Exchange Corporate Adviser: Cairn Financial Advisers LLP Jo Turner/James Lewis +44 (0) 20 7213 0880 Broker: Stanford Capital Partners Ltd Patrick Claridge/John Howes/Bob Pountney +44 (0) 20 3815 8880
Notes to Editors
Incanthera is a specialist oncology company focused on innovative technologies in oncology and dermatology . It seeks to identify and develop innovative solutions to current clinical, commercially relevant unmet needs, utilising new technology from leading academic institutions.
The Company's current lead product and focus is Sol, a potentially innovative topical product for the treatment of solar keratosis and the prevention of skin cancers. This has achieved proof of concept and the Company is now focussed upon delivering Sol to a commercial partner.
The Company originated from the Institute of Cancer Therapeutics ("ICT") at the University of Bradford and has acquired and developed a portfolio of specific cancer-targeting therapeutics through a Pipeline Agreement with the ICT and other corporate acquisitions.
Incanthera's strategy is to develop each candidate in the portfolio from initial acquisition or discovery to securing its future through commercially valuable partnerships at the earliest opportunity in its development pathway.
For more information on the Company please visit: www.incanthera.com
@incantheraplc
This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.
RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.
END
NEXPPUQABUPPGGM
(END) Dow Jones Newswires
September 27, 2022 07:58 ET (11:58 GMT)
1 Year Incanthera Chart |
1 Month Incanthera Chart |
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.
Support: +44 (0) 203 8794 460 | support@advfn.com
By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions
Hot Features
Premium
